Ranbaxy launches generic Caduet in US
New York: Drugmaker Ranbaxy Laboratories (RANB.NS) said on Tuesday its unit has launched a generic version of Pfizer's (PFE.N) blood pressure- and cholesterol-lowering drug Caduet in the United States following an agreement between the two companies.
Caduet has annual sales of USD 339 million in the United States, the Indian firm said in a statement.
The terms of the agreement were not disclosed.
Ranbaxy, majority-owned by Japan's Daiichi Sankyo (4568.T), last week launched a generic version of Lipitor, the world's top selling drug, which is also a Pfizer brand.